Abstract
In the face of the global COVID-19 pandemic, the need arose to investigate potential complications associated with SARS-CoV-2, including the risk of Stroke.
Objective This study aimed to verify the association between SARS-CoV-2 and the risk of Stroke, based on systematic reviews and meta-analyses, in order to assess the inclusion of the virus as a new risk factor for cerebrovascular diseases.
Methods A metaumbrella was conducted, which included 34 systematic reviews, of which 4 were selected for the final analysis based on methodological quality and consistency. The analysis aggregated the results of 70 primary studies, considering different stroke subtypes and outcomes associated with COVID-19. Study heterogeneity was assessed using the I² index, and significance bias was verified using Egger’s test.
Results The analysis showed that the severity of COVID-19 is significantly associated with an increased risk of stroke (eOR = 2.48; 95%CI: 1.55 – 3.95), particularly for ischemic stroke (eOR = 1.76; 95%CI: 1.11 – 2.80) and hemorrhagic stroke (eOR = 3.86; 95%CI: 1.79 – 8.33). Additionally, patients with cerebrovascular comorbidities had higher mortality (eOR = 2.48; 95%CI: 2.48 – 19.63), as did those who had previously suffered a stroke (eOR = 6.08; 95%CI: 3.73 – 9.91).
Conclusion The association between SARS-CoV-2 and stroke was consistent and significant, suggesting that COVID-19 should be considered a new risk factor for cerebrovascular diseases. However, the high heterogeneity among the studies analyzed reinforces the need for further research to consolidate this relationship.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) did not receive financial support for the research, authorship and/or publication of this article.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Association between SARS-CoV-2 and Stroke: Perspectives from metaumbrella-review.
Data Availability
All worksheets can be provided by the corresponding author through the email request andrezamlb{at}gmail.com
